D. Boral Capital Reiterates Buy Rating for Cytosorbents (NASDAQ:CTSO)

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Cytosorbents (NASDAQ:CTSO) with a target price of $10.00 per share, indicating potential for significant growth.
• Cytosorbents has reported a net margin of -41.77% and a revenue slightly below estimates, with the company facing ongoing financial challenges.
• Institutional investors have increased their stakes in Cytosorbents, with Goldman Sachs Group boosting its position by 149.2% in the first quarter.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $10.00 target price on the medical research company's stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright restated a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Thursday, May 15th. Wall Street Zen initiated coverage on shares of Cytosorbents in a report on Wednesday, May 21st. They issued a "hold" rating on the stock.

Cytosorbents Price Performance

Cytosorbents stock opened at $0.89 on Friday. The firm has a market cap of $55.92 million, a PE ratio of -3.19 and a beta of 1.19. Cytosorbents has a 52-week low of $0.71 and a 52-week high of $1.61. The company has a quick ratio of 2.30, a current ratio of 2.61 and a debt-to-equity ratio of 0.98. The company's 50 day moving average is $1.05 and its two-hundred day moving average is $1.03.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. Cytosorbents had a negative net margin of 41.77% and a negative return on equity of 105.04%. The company had revenue of $9.62 million for the quarter, compared to analyst estimates of $9.79 million. On average, research analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after buying an additional 37,519 shares during the last quarter. Avenir Corp grew its position in shares of Cytosorbents by 63.1% in the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company's stock valued at $5,045,000 after buying an additional 1,950,972 shares during the last quarter. CM Management LLC grew its position in shares of Cytosorbents by 36.3% in the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock valued at $954,000 after buying an additional 254,076 shares during the last quarter. Skylands Capital LLC grew its position in Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after purchasing an additional 221,080 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC grew its position in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after purchasing an additional 43,900 shares during the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.